Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13569223 | 0.98 | HRH3 (0.72) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| SCHEMBL12668355 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| SCHEMBL6921327 | 0.83 | HRH3 (0.72) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| SCHEMBL13990825 | 0.83 | HRH3 (1.00) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| SCHEMBL7408809 | 0.83 | HRH3 (0.59) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| SCHEMBL17538302 | 0.82 | HRH3 (0.50) | CYP1A2CYP2D6HRH3L3MBTL1MBTD1 | |
| SCHEMBL29036781 | 0.81 | CYP1A2 (0.63) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| SCHEMBL15198045 | 0.78 | CYP1A2 (0.68) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16237943 | 0.76 | HRH3 (0.69) | CYP1A2HRH3CYP3A4L3MBTL1MBTD1 | |
| SCHEMBL12937131 | 0.76 | EPHX2 (0.59) | CYP1A2CYP2D6HRH3SIGMAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | CYP1A2 844/4885CYP2D6 508/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.